A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Able and willing to comply with all protocol-related activities
Willing and able to provide written informed consent
You may not be if
Any significant concurrent condition that could adversely affect participation
Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022
Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities